Celltrion, Inc.
23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com
版塊: Healthcare
行業: Biotechnology
全職員工:
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Hyong-Gi Kim | CEO & Internal Director | 無 | 無 | 1965 |
| Mr. Woo-Sung Kee | CEO & Internal Director | 無 | 無 | 1961 |
| Jin-seok Seo | Co-CEO & Inside Co-Chairman of the Board | 無 | 無 | 無 |
| Mr. Stephen Yeum | Founder | 無 | 無 | 無 |
| Mr. Min-Cheol Shin | Director of Finance | 無 | 無 | 1971 |
| Mr. Ji-Hoon Choi | Director of Legal Affairs | 無 | 無 | 1971 |
描述
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
公司管治
截至 2024年5月1日 止，Celltrion, Inc. 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：1；董事會：4；股東權利：4；現金賠償：1。
